Overview

NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma

Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of NOX A12 alone and in combination with a background therapy of bortezomib and dexamethasone (VD) chemotherapy in previously treated patients with multiple myeloma (MM).
Phase:
Phase 2
Details
Lead Sponsor:
NOXXON Pharma AG
Treatments:
BB 1101
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate